KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Depreciation and Depletion (2018 - 2025)

Castle Biosciences' Depreciation and Depletion history spans 7 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 5.11% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $5.9 million, up 21.3%, while the annual FY2025 figure was $5.9 million, 21.3% up from the prior year.
  • Depreciation and Depletion for Q4 2025 was $1.5 million at Castle Biosciences, down from $1.5 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $1.5 million in Q3 2025 and bottomed at $233000.0 in Q1 2021.
  • The 5-year median for Depreciation and Depletion is $847000.0 (2023), against an average of $893350.0.
  • The largest annual shift saw Depreciation and Depletion surged 270.59% in 2021 before it rose 5.11% in 2025.
  • A 5-year view of Depreciation and Depletion shows it stood at $442000.0 in 2021, then surged by 41.86% to $627000.0 in 2022, then soared by 51.99% to $953000.0 in 2023, then skyrocketed by 49.84% to $1.4 million in 2024, then increased by 5.11% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Depreciation and Depletion are $1.5 million (Q4 2025), $1.5 million (Q3 2025), and $1.5 million (Q2 2025).